Immunic, Inc. (IMUX) News
Follow Immunic, Inc. (IMUX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 11 public stories across 6 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Dr. Duane Nash resigns from Immunic board; board reduced to nine members
Immunic said Dr. Duane Nash resigned from its Board of Directors, and the Board was reduced from ten to nine members.Original SEC Filing: IMMUNIC, INC. [ IMUX ] - 8-K - Sep. 11, 2026This is an AI-powered summary. It may
REGULATION | Sep 11, 2026, 09:34 PM UTC
L
Immunic price target maintained at $45.00 by Wedbush
EQUITY | Sep 10, 2026, 01:19 PM UTC
L
HC Wainwright maintains $22.00 price target for IMUX
EQUITY | Sep 10, 2026, 10:22 AM UTC
M
IMUX expects pivotal phase III vidofludimus calcium data by year-end
Vidofludimus calcium is advancing through pivotal phase III trials in relapsing MS. The program targets key data readouts by year-end and aims for an NDA submission next year.
EQUITY | Sep 09, 2026, 07:04 PM UTC
M
IMUX nears pivotal Phase III readouts for vidofludimus calcium in relapsing MS
IMUX says vidofludimus calcium is nearing pivotal Phase III readouts in relapsing MS. The oral therapy targets both inflammatory and neurodegenerative mechanisms, aiming to address unmet needs in efficacy and safety.
EQUITY | Sep 09, 2026, 05:55 PM UTC
M
IMUX expects pivotal Phase 3 vidofludimus calcium data by end-2026
IMUX is advancing vidofludimus calcium through pivotal Phase 3 trials in relapsing MS. Top-line data are expected by end of 2026, with a U.S. NDA submission targeted for mid-2027.
EQUITY | Sep 09, 2026, 04:43 PM UTC
L
Immunic hosts RMS R&D Day webinar, outlines vidofludimus plans
Immunic said it is hosting a relapsing multiple sclerosis R&D Day webinar and presented vidofludimus calcium development plans in an original SEC filing.
REGULATION | Sep 09, 2026, 01:03 PM UTC
L
IMUX to host virtual R&D Day on September 9, 2026
IMUX said it will host a virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026.
EQUITY | Sep 02, 2026, 10:30 AM UTC
L
IMUX appoints Chitrang Davé as Chief Data and Digital Officer
IMUX appointed Chitrang Davé as Chief Data and Digital Officer.
EQUITY | Sep 01, 2026, 10:30 AM UTC
L
Immunic appoints Chitrang Davé as Chief Data and Digital Officer
Immunic (IMUX) appointed Chitrang Davé as Chief Data and Digital Officer, creating a new C-suite role focused on building a commercial-ready data ecosystem ahead of a potential NDA submission and commercialization.
EQUITY | Sep 01, 2026, 10:30 AM UTC
L
IMUX looks undervalued ahead of a key Q426 Phase 3 relapsing MS readout @ Briley
IMUX looks undervalued ahead of a key Q426 Phase 3 relapsing MS readout @ Briley
EQUITY | Jul 20, 2026, 01:07 PM UTC